·¢±íÖ÷Ìâ
ÂÛ̳Ê×Ò³ ÍƼöÖ÷Ìâ Ö÷Ìâר¼­ °®Ò½Åàѵ °®Ò½ÔÓÖ¾ Ç©Ô¼×÷Õß ÈÙÓþÑ«Õ ÅÅÐаñ ÎÒµÄÖ÷Ò³
²é¿´: 3260|»Ø¸´: 14
´òÓ¡ ÉÏÒ»Ö÷Ìâ ÏÂÒ»Ö÷Ìâ

[´ðÒɽ»Á÷] Ϊʲô˵ITPÒ²ÊÇÒ»ÖÖѪ˨ǰ¼²²¡£¿

[¸´ÖÆÁ´½Ó]
Ìøתµ½Ö¸¶¨Â¥²ã
1# Â¥Ö÷
·¢±íÓÚ 2014-8-21 17:38 | Ö»¿´¸Ã×÷Õß »ØÌû½±Àø |µ¹Ðòä¯ÀÀ |ÔĶÁģʽ

ÂíÉÏ×¢²á£¬½á½»¸ü¶àºÃÓÑ£¬ÏíÓøü¶à¹¦ÄÜ£¬ÈÃÄãÇáËÉÍæתÉçÇø¡£

ÄúÐèÒª µÇ¼ ²Å¿ÉÒÔÏÂÔØ»ò²é¿´£¬Ã»ÓÐÕʺţ¿×¢²á

x
Ϊʲô˵ITPÒ²ÊÇÒ»ÖÖѪ˨ǰ¼²²¡£¿°Ë°æ½Ì²ÄËùÊöÈçͼ
2# ɳ·¢
·¢±íÓÚ 2014-8-21 22:01 | Ö»¿´¸Ã×÷Õß
ÃâÒßÓÕµ¼µÄѪС°å¾Û¼¯ÐγÉѪ˨¡£
15Â¥
·¢±íÓÚ 2017-9-27 10:03 | Ö»¿´¸Ã×÷Õß
¿ÉÄܵĻúÖÆ£ºÓÐÑо¿·¢ÏÖÔ¼Èý·ÖÖ®Ò»µÄITP»¼Õß´æÔÚ¿¹Á×Ö¬¿¹Ìå[1]¡¢ITP»¼Õß´æÔÚןü¸ßˮƽµÄѪС°åÔ´ÐÔ΢¿ÅÁ£[2]¡¢¼°¿¹Ìå°ü±»µÄѪС°åÄÜ´Ù½ø²¹Ì弤»î[3]£¬ÁíÍâITP»¼ÕßѪС°å±¾Éí¸üÄêÇá¡¢»îÐÔ¸ü¸ß£¬ÖÎÁƺóѪС°åÊýÁ¿ÉýµÃ¹ý¿ìµÈÒ²ÊÇ¿ÉÄܵÄÔ­Òò¡£ËùÒÔITPÖÎÁƲ»Ó¦ÊÔͼ½«PLT¼ÆÊýÉýÖÁÕý³£Ë®Æ½£¬3ÍòÒÔÉϼ´¿É£¬³¬¹ý5Íòʱ¶ÔͬʱºÏ²¢ÆäËûѪ˨·çÏյĻ¼ÕßÒª¿¼ÂÇ¿¹Äý´ëÊ©¡£ 1. Diz-Kucukkaya R, Hacehanefioglu A, Yenerel M et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood. 2001;98:1760-1764. 2. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med. 1992;119:334-345. 3. Peerschke EI, Yin W, Ghebrehiwet B. Complement activation on platelets: implications for vascular inflammation and thrombosis. Mol Immunol. 2010;47:2170-2175.
ÄúÐèÒªµÇ¼ºó²Å¿ÉÒÔ»ØÌû µÇ¼ | ×¢²á

±¾°æ»ý·Ö¹æÔò

Archiver|ÊÖ»ú°æ|¹ØÓÚÎÒÃÇ|Òþ˽±£»¤|°æȨ±£»¤|СºÚÎÝ|°®°®Ò½ ( ÔÁICP±¸2023094852ºÅ )

GMT+8, 2024-4-27 03:31

Powered by Discuz! X3.1

© 2001-2013 Comsenz Inc.